《2024.V1版卵巢癌包括输卵管癌和原发性腹膜癌》NCCN证据块指南解读OACSTPCD
Interpretation of the NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)with NCCN Evidence Blocks™——Ovarian Cancer Including Fal-lopian Tube Cancer and Primary Peritoneal Cancer(2024 Version 1)
卵巢恶性肿瘤是妇科三大恶性肿瘤之一,其发病率较低,但死亡率较高,并且近20年死亡率仍然处于升高趋势.卵巢癌常呈现出频繁复发需多程化疗的特点,目前美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)指南已有针对各阶段卵巢癌的化疗方案推荐,但是同级别推荐的不同化疗方案如何选择仍不明确.鉴于此,NCCN于2015年发布带有证据块的NCCN指南,其从E.方案/药物的疗效;S.方案/药物的安全性;Q.证据质量;C.证据的一致性;A.方案/药物的可负担性,5个维度对不同化疗方案进行比较,以便根据患者不同病情及个人状况选择更合适的化疗方案,从而实现个体化、精准化治疗.
Ovarian malignant tumor is one of the three major malignant tumors in gynecology.It has a low incidence rate but a high mortality rate,and the mortality rate is still in an increasing trend in the last 20 years.The course of ovarian canc-er is often manifested as frequent recurrence requiring multi-course chemotherapy.At present,National Comprehensive Cancer Network(NCCN)guidelines have recommended chemotherapy regimens for all stages of ovarian cancer,but how to choose different chemotherapy regimens recommended at the same level remains unclear.NCCN released Clinical Practice Guidelines in Oncology(NCCN Guidelines)with NCCN Evi-dence Blocks™ in 2015,which compares different chemothera-peutic regimens in five dimensions:E.efficacy of regimens/drugs;S.safety of regimens/drugs;Q.quality of evidence;C.consistency of evidence;and A.affordability of regimens/drugs,in order to choose more suitable chemotherapy regimens ac-cording to patients'different conditions and personal status,thus achieving individualized and precise treatment.
张鹏闯;胡丽娟;吴涛;胡媛;王国庆
710061 西安,陕西省肿瘤医院妇瘤科710068 西安,陕西省人民医院放疗科
临床医学
卵巢癌输卵管癌原发性腹膜癌证据块指南解读
Ovarian cancerFallopian tube cancerPrimary peritoneal cancerEvidence blocksGuideline interpretation
《肿瘤预防与治疗》 2024 (005)
372-384 / 13
This study was supported by grants from Science and Technology Department of Shaanxi Province(No.S2023-JC-QN-1665)and Beijing Science and Technology Innovation Medical Development Foundation(No.KC2021-JX-1086-134). 陕西省自然科学基础研究计划资助项目(编号:S2023-JC-QN-1665);北京科创医学发展会齐鲁肿瘤疾病研究基金项目(编号:KC2021-JX-1086-134)
评论